Fluphenazine Decanoate (Depot) and Enanthate for Schizophrenia (Review)

Total Page:16

File Type:pdf, Size:1020Kb

Fluphenazine Decanoate (Depot) and Enanthate for Schizophrenia (Review) Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 2 http://www.thecochranelibrary.com Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 6 METHODS ...................................... 6 RESULTS....................................... 11 Figure1. ..................................... 13 Figure2. ..................................... 16 Figure3. ..................................... 17 ADDITIONALSUMMARYOFFINDINGS . 24 DISCUSSION ..................................... 30 AUTHORS’CONCLUSIONS . 32 ACKNOWLEDGEMENTS . 33 REFERENCES ..................................... 33 CHARACTERISTICSOFSTUDIES . 50 DATAANDANALYSES. 160 Analysis 1.1. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 1 Death. 170 Analysis 1.2. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 2 Global state: 1. Relapse. 171 Analysis 1.3. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 3 Global state: 2. GAS (short term - 6 weeks to 5 months) (high score = worse). 172 Analysis 1.4. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 4 Leaving the study early. 173 Analysis 1.5. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 5 Mental state: 1. BPRS (endpoint scores - high score = worse). 174 Analysis 1.6. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 6 Mental state: 2. Depression (mediumterm-6monthsto1year).. 174 Analysis 1.7. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 7 Adverse effects: 1. Movement disorders - tardive dyskinesia (longer term - more than 1 year).................. 175 Analysis 1.8. Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 8 Adverse effects: 2. Toxicity. 175 Analysis 2.1. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 1 Global state: 1. No clinically important global change. 176 Analysis 2.2. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 2 Global state: 2. Relapse..................................... 177 Analysis 2.3. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 3 Global state: 3. Clinical Global Impression (short term - 6 weeks to 5 months) (high score = worse). 178 Analysis 2.4. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 4 Leaving the studyearly.................................... 179 Analysis 2.5. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 5 Behaviour: 1. NOSIE-30 - endpoint scores (high score = poor). 180 Analysis 2.7. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 7 Mental state: 1. BPRS - endpoint scores (longer term - more than 1 year) (high score =poor).. ... ... ... .. 181 Analysis 2.8. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 8 Mental state: 2. Depression. .................................. 182 Analysis 2.9. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 9 Adverse effects: 1a.Movementdisorders-general. 183 Analysis 2.10. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 10 Adverse effects: 1b. Movement disorders - akathisia. .......... 184 Analysis 2.11. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 11 Adverse effects: 1c. Movement disorders - needing anticholinergic drugs. ................ 185 Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) i Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 2.12. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 12 Adverse effects: 1d. Movement disorders - tardive dyskinesia. ............... 186 Analysis 2.13. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 13 Adverse effects: 1e. Movement disorders - tremor (longer term - more than1year).. 187 Analysis 2.14. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 14 Adverse effects: 1f. Movement disorders - average score (Simpson & Angus, 0 to 5 weeks, high = poor). 187 Analysis 2.15. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 15 Adverse effects: 2. Blurred vision - medium term (6 months to 1 year). .............. 188 Analysis 2.16. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 16 Adverse effects: 3. Toxicity - medium term (6 months to 1 year). .......... 188 Analysis 2.17. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 17 Adverse effects:4.Generaladverseeffects. 189 Analysis 2.18. Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 18 SENSITIVITY ANALYSIS Global state: 2. Relapse. .......... 190 Analysis 3.1. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 1 Death. .................................... 191 Analysis 3.2. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 2 Global state: 1. No clinically important global change. .............. 191 Analysis 3.3. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 3 Globalstate:2.Relapse. 192 Analysis 3.4. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 4 Global state: 3. Severly ill (medium term 6 months to 1 year). ............... 194 Analysis 3.5. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 5 Global state: 4. Needing additional antipsychotic treatment(6monthsto1year). 194 Analysis 3.7. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 7 Global state: 6. Clinical Global Impression. (medium term - 6 monthsto1year). 195 Analysis 3.8. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 8 Global state: 7. Clinical Global Impression - not improved (high score = poor). 196 Analysis 3.9. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 9 Leavingthestudyearly. 197 Analysis 3.10. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Behaviour: 1. NOSIE-30 - endpoint scores (high score = poor). ............. 199 Analysis 3.11. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Mental state: 1. BPRS (endpoint scores - high score = poor). ............. 199 Analysis 3.12. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year - dichotomous data). 200 Analysis 3.13. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 13 Mental state: 3. Depression (6 months to 1 year). ......... 201 Analysis 3.15. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 15 Adverse effects: 1a. Movement disorders - general. ............. 202 Analysis 3.16. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 16 Adverse effects: 1b. Movement disorders - needing anticholinergic drugs. 203 Analysis 3.17. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 17 Adverse effects: 1c. Movement disorders - parkinsonism. ............... 204 Analysis 3.18. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 18 Adverse effects: 1d. Movement disorders - tardive dyskinesia: longer term (more than 1 year). 205 Analysis 3.19. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 19 Adverse effects: 1e. Movement disorders - tremor. ............ 206 Analysis 3.21. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 21 Adverseeffects:2.Blurredvision. 207 Analysis 3.22. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 22 Adverse effects: 3. Dry mouth: longer term (more than 1 year). ............... 208 Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) ii Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 3.23. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 23 Adverseeffects:4.Generaladverseeffects. .......... 208 Analysis 3.24. Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 24 SENSITIVITY ANALYSIS Global state: 2. Relapse. .......... 209 Analysis 4.1. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 1 Global state: 1. Relapse (medium term - 6 months to 1 year). ............. 210 Analysis 4.2. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 2 Global state: 2. Needing additional antispsychotic treatment (medium term - 6 months to 1 year). 211 Analysis 4.3. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 3 Global state: 3. Not improved (medium term - 6 months to1year).. 212 Analysis 4.4. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 4 Leaving the study early (medium term - 6 months to 1 year). ............. 213 Analysis 4.5. Comparison 4 FLUPHENAZINE DECANOATE - DOSAGE STUDIES - HIGH DOSE vs STANDARD, Outcome 5 Mental state: BPRS endpoint scores (medium term - 6 months to 1 year, high score = poor). 213 Analysis 4.6. Comparison 4 FLUPHENAZINE
Recommended publications
  • Product Monograph
    PRODUCT MONOGRAPH PrFLUANXOL® Flupentixol Tablets (as flupentixol dihydrochloride) 0.5 mg, 3 mg, and 5 mg PrFLUANXOL® DEPOT Flupentixol Decanoate Intramuscular Injection 2% and 10% flupentixol decanoate Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel December 12th, 2017 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 209135 Page 1 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................15 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................19 STORAGE AND STABILITY ..........................................................................................21
    [Show full text]
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • DOCTORAL THESIS Effects of Glucocorticoid Overload on Central
    DOCTORAL THESIS Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders Ahmad, Rabia Award date: 2013 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 “Effects of glucocorticoid overload on central regulatory systems involved in responses to stress – preclinical investigations into putative molecular targets in neuroimaging of stress-related mood disorders” By Rabia Ahmad, BSc (Hons). A thesis submitted in partial fulfilment of the requirements for the degree of PhD Department of Life Sciences University of Roehampton 2013 Abstract Irregularities of the Hypothalamic Pituitary Adrenal (HPA) axis are implicated in stress-related mood disorders. The ensuing long-term elevations in circulating glucocorticoids are associated with neurobiological changes seen in depression. This thesis aims to identify some of the brain mechanisms by which exposure to chronic stress may lead to depression using a preclinical experimental approach.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Revision of Precautions Asenapine Maleate, Aripiprazole, Olanzapine
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Asenapine maleate, aripiprazole, olanzapine, quetiapine fumarate, clocapramine hydrochloride hydrate, chlorpromazine hydrochloride, chlorpromazine hydrochloride/promethazine hydrochloride/phenobarbital, chlorpromazine phenolphthalinate, spiperone, zotepine, timiperone, haloperidol, paliperidone, pipamperone hydrochloride, fluphenazine decanoate, fluphenazine maleate, brexpiprazole, prochlorperazine maleate, prochlorperazine mesilate, Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. propericiazine, bromperidol, perphenazine, perphenazine hydrochloride, perphenazine fendizoate, perphenazine maleate, perospirone hydrochloride hydrate, mosapramine hydrochloride, risperidone (oral drug), levomepromazine hydrochloride, levomepromazine maleate March 27, 2018 Non-proprietary name Asenapine maleate,
    [Show full text]
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D
    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
    [Show full text]
  • Psychiatric Medications in Behavioral Healthcarev5
    Copyright © The University of South Florida, 2012 Psychiatric Medications in Behavioral Healthcare An Important Notice None of the pages in this tutorial are meant to be a replacement for professional help. The science of medicine is constantly changing, and these changes alter treatment and drug therapies as a result of what is learned through research and clinical experience. The author has relied on resources believed to be reliable at the time material was developed. However, there is always the possibility of human error or changes in medical science and neither the authors nor the University of South Florida can guarantee that all the information in this program is in every respect accurate or complete and they are not responsible for any errors or omissions or for the results obtained from the use of such information. Each person that reads this program is encouraged to confirm the information with other sources and understand that it not be interpreted as medical or professional advice. All medical information needs to be carefully reviewed with a health care provider. Course Objectives At the completion of this program participants should be able to: • Identify at 5 categories of medications used to treat the symptoms of psychiatric disorders, the therapeutic effects of medications in each category, and the side effects associated with medications in each category. • Identify at least 5 medications and the benefits of those medications as compared to the medications. • Identify at least 5 reasons that a person may stop taking medications or not take medications as prescribed. • Demonstrate your learned understanding of psychiatric medications by passing the combined post‐ tests.
    [Show full text]
  • Cochrane Database of Systematic Reviews
    Fluphenazine decanoate (depot) and enanthate for schizophrenia Author Maayan, Nicola, Quraishi, Seema N, David, Anthony, Jayaswal, Aprajita, Eisenbruch, Maurice, Rathbone, John, Asher, Rosie, Adams, Clive E Published 2015 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD000307.pub2 Copyright Statement © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD000307. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/391173 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD000307. DOI: 10.1002/14651858.CD000307.pub2. www.cochranelibrary.com Fluphenazine decanoate (depot) and enanthate for schizophrenia (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley
    [Show full text]
  • Monoamine Depletion in Psychiatric and Healthy Populations
    Molecular Psychiatry (2003) 8, 951–973 & 2003 Nature Publishing Group All rights reserved 1359-4184/03 $25.00 www.nature.com/mp FEATURE REVIEW Monoamine depletion in psychiatric and healthy populations: review L Booij1, AJW Van der Does1,2 and WJ Riedel3,4,5 1Department of Psychology, Leiden University, Leiden 2333 AK, The Netherlands; 2Department of Psychiatry, Leiden University, Leiden 2333 AK, The Netherlands; 3GlaxoSmithKline, Translational Medicine & Technology, Cambridge, UK; 4Department of Psychiatry, University of Cambridge, UK; 5Faculty of Psychology, Maastricht University, The Netherlands A number of techniques temporarily lower the functioning of monoamines: acute tryptophan depletion (ATD), alpha-methyl-para-tyrosine (AMPT) and acute phenylalanine/tyrosine deple- tion (APTD). This paper reviews the results of monoamine depletion studies in humans for the period 1966 until December 2002. The evidence suggests that all three interventions are specific, in terms of their short-term effects on one or two neurotransmitter systems, rather than on brain protein metabolism in general. The AMPT procedure is somewhat less specific, affecting both the dopamine and norepinephrine systems. The behavioral effects of ATD and AMPT are remarkably similar. Neither procedure has an immediate effect on the symptoms of depressed patients; however, both induce transient depressive symptoms in some remitted depressed patients. The magnitude of the effects, response rate and quality of response are also comparable. APTD has not been studied in recovered major depressive patients. Despite the similarities, the effects are distinctive in that ATD affects a subgroup of recently remitted patients treated with serotonergic medications, whereas AMPT affects recently remitted patients treated with noradrenergic medications.
    [Show full text]